Edition:
United Kingdom

Akorn Inc (AKRX.O)

AKRX.O on Nasdaq

33.01USD
19 Jan 2018
Change (% chg)

$-0.05 (-0.15%)
Prev Close
$33.06
Open
$33.03
Day's High
$33.18
Day's Low
$32.72
Volume
1,865,843
Avg. Vol
2,021,968
52-wk High
$34.00
52-wk Low
$17.74

Chart for

About

Akorn Inc. (Akorn), together with its subsidiaries, is a specialty generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals, as well as private-label over-the-counter (OTC) consumer health products and animal health pharmaceuticals. The Company operates through two... (more)

Overall

Beta: 1.34
Market Cap(Mil.): $4,101.01
Shares Outstanding(Mil.): 124.92
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

Fresenius CFO backs acquisition course - Boersen-Zeitung

FRANKFURT German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying.

07 Jan 2018

Fresenius CFO backs acquisition course: Boersen-Zeitung

FRANKFURT German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying.

07 Jan 2018

Fresenius CFO backs acquisition course -Boersen-Zeitung

FRANKFURT, Jan 7 German healthcare group Fresenius will continue to look for acquisitions even if that leads to a temporary rise in debt, Boersen-Zeitung quoted the company's finance chief as saying.

07 Jan 2018

REFILE-Fresenius now sees completion of Akorn takeover in early 2018

FRANKFURT, Dec 19 Fresenius now expects its planned takeover of Akorn, a U.S. maker of liquid generic drugs, to be completed in early 2018 rather than this year, a spokesman for Fresenius said on Tuesday.

19 Dec 2017

Fresenius says Akorn deal closure could take until next year

FRANKFURT German healthcare group Fresenius SE said the planned takeover of Akorn , a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected.

22 Nov 2017

Fresenius says Akorn deal closure could take until next year

FRANKFURT, Nov 22 German healthcare group Fresenius SE said the planned takeover of Akorn , a U.S. maker of liquid generic drugs, might not be completed before next year as the U.S. antitrust review could take longer than expected.

22 Nov 2017

UPDATE 1-Fresenius says Akorn troubles could continue into next year

FRANKFURT, Nov 2 German healthcare group Fresenius SE said on Thursday that weakness at Akorn , the U.S. maker of liquid generic drugs it has agreed to buy, could continue into next year but the deal was still worth it over the longer term.

02 Nov 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

31 Oct 2017

Insys founder Kapoor steps down as Akorn chairman after arrest

NEW YORK, Oct 31 John Kapoor, the billionaire founder of opioid maker Insys Therapeutics Inc, has resigned as chairman of drugmaker Akorn Inc, just days after his arrest on charges he participated in a scheme to bribe doctors to prescribe a potent pain medication while he was at Insys.

31 Oct 2017

Billionaire Insys founder charged in U.S. opioid bribe case

BOSTON The billionaire founder of Insys Therapeutics Inc was arrested on Thursday on U.S. charges he participated in a scheme to bribe doctors to prescribe a fentanyl-based cancer pain drug, marking a step by authorities to fight the opioid epidemic.

27 Oct 2017

Earnings vs. Estimates